# Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer

> **NCT02312622** · PHASE2 · COMPLETED · sponsor: **Joel Neal** · enrollment: 27 (actual)

## Conditions studied

- Stage IV Non-small Cell Lung Cancer (NSCLC)
- Recurrent Non-small Cell Lung Cancer (NSCLC)
- Extensive-stage Small Cell Lung Cancer (SCLC)
- Recurrent Small Cell Lung Cancer (SCLC)
- Tumors Metastatic to Brain
- Metastatic Breast Cancer (mBC)

## Interventions

- **DRUG:** Pegylated Irinotecan

## Key facts

- **NCT ID:** NCT02312622
- **Lead sponsor:** Joel Neal
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2018-09-08
- **Final completion:** 2019-07
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2023-12-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02312622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02312622, "Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02312622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*